Drug Trial Radar · NCT06744647
Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation
Last checked: Nov 20, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
47
Actual
Start
Mar 7, 2025
Primary completion
Oct 11, 2027
Study completion Nov 7, 2028
Sponsor
- Lead sponsor
- Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Dec 20, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the efficacy of ALXN2030 compared with placebo on biopsy proven histologic resolution in participants with active or chronic active antibody-mediated rejection (AMR) at Week 52.
Conditions
- Antibody-Mediated Rejection
- Kidney Transplantation
- Biopsy-proven Histologic Scores
- AMR
Interventions
ALXN2030Drug
ALXN2030 will be administered subcutaneously (SC).
PlaceboDrug
Placebo will be administered SC.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Biopsy-proven histologic resolutionTime frame: Week 52
Locations
51 sites in 8 countries. Site status is shown where the registry gives one.
Research Site
Birmingham, Alabama
Research Site
Scottsdale, Arizona
Research Site
Los Angeles, California
Research Site
Orange, California
Research Site
Tampa, Florida
Research Site
Atlanta, Georgia
Research Site
Kansas City, Kansas
Research Site
Ann Arbor, Michigan
Research Site
Detroit, Michigan
Research Site
Livingston, New Jersey
Research Site
New York, New York
Research Site
New York, New York
Research Site
New York, New York
Research Site
Durham, North Carolina
Research Site
Cincinnati, Ohio
Research Site
Philadelphia, Pennsylvania
Research Site
Dallas, Texas
Research Site
Houston, Texas
Research Site
Richmond, Virginia
Research Site
Seattle, Washington
Research Site
Milwaukee, Wisconsin
Research Site
Botucatu, Brazil
Research Site
Campinas, Brazil
Research Site
Porto Alegre, Brazil
Research Site
São Paulo, Brazil
Research Site
São Paulo, Brazil
Research Site
Calgary, Alberta, Canada
Research Site
Edmonton, Alberta, Canada
Research Site
Vancouver, British Columbia, Canada
Research Site
London, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Changsha, China
Research Site
Guangzhou, China
Research Site
Nanning, China
Research Site
Shanghai, China
Research Site
Wuhan, China
Research Site
Xi'an, China
Research Site
Seoul, South Korea
Research Site
Seoul, South Korea
Research Site
Seoul, South Korea
Showing 40 of 51 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.